Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response

1992 ◽  
Vol 30 (S1) ◽  
pp. S37-S40 ◽  
Author(s):  
Iwao Fukui ◽  
Kazunori Kihara ◽  
Hideaki Sekine ◽  
Yuichi Tachibana ◽  
Tsuneo Kawai ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Randomized Trial ◽  
Mitomycin C ◽  
Combination Chemotherapy ◽  
Superficial Bladder Cancer ◽  
Complete Response

1570: Combined Mitomycin C and Hyperthermia (SYNERGO) for Patients with Superficial Bladder Cancer (SBC) after Bacillus Calmette-Guerin (BCG) Failure

2007 ◽  
Vol 177 (4S) ◽  
pp. 519-519
Author(s):  
Ofer Nativ ◽  
Renzo Colombo ◽  
Dov Engelstein ◽  
Ofer N. Gofrit ◽  
Thomas Akkad ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Bcg Failure

832: Optimized Intravesical Mitomycin C Treatment for Superficial Bladder Cancer: Long-Term Follow-Up

2006 ◽  
Vol 175 (4S) ◽  
pp. 268-269 ◽  
Author(s):  
Jessie L. Au ◽  
Robert A. Badalament ◽  
M. Guillaume Wientjes ◽  
Donn C. Young ◽  
Tong Shen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Long Term Follow Up

A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer

1994 ◽  
Vol 35 (S1) ◽  
pp. S31-S35 ◽  
Author(s):  
Kikuo Okamura ◽  
Tatsuro Murase ◽  
Koji Obata ◽  
Shinichi Ohshima ◽  
Yoshinari Ono ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Randomized Trial ◽  
Superficial Bladder Cancer ◽  
Intravesical Instillation

Multi-institutional review of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle-invasive bladder cancer.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 294-294
Author(s):  
Andrew J. Lightfoot ◽  
Benjamin N. Breyer ◽  
Henry M. Rosevear ◽  
Badrinath Konety ◽  
Michael A. O'Donnell
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Median Time ◽  
Combination Chemotherapy ◽  
Invasive Bladder Cancer ◽  
Intravesical Therapy ◽  
Recurrence Free Survival ◽  
Muscle Invasive Bladder Cancer ◽  
Free Survival ◽  
Muscle Invasive

294 Background: Combination chemotherapy is the standard of care for neoadjuvant, adjuvant, and metastatic bladder cancer due to increased efficacy when compared to monotherapy. We report our experience with sequential intravesical combination chemotherapy using gemcitabine and mitomycin C (MMC) for non-muscle invasive bladder cancer (NMIBC). Methods: We performed a multi-institutional retrospective review of 47 consecutive patients who received 6 weekly treatments with sequential gemcitabine (1g) and mitomycin C (40mg) chemotherapy for NMIBC. Thirty patients received treatment at University of Iowa, 14 at UCSF and 3 at University of Minnesota. Results: A total 47 patients (median age 70, range 32-85; 36 males, 11 females) previously failing a median of 2 intravesical treatments were reviewed. The complete response (CR), 1-year recurrence-free survival (1-RFS) and 2-year recurrence-free survival (2-RFS) for all patients was 68%, 48% and 38%, respectively. In all, 14 of 47 patients (30%) remain free of recurrence with a median time to followup of 26 months (range 6-80 months). The median time to recurrence for all patients who recurred was 4 months (range 1-33 months). Ten patients required cystectomy. Conclusions: Sequential intravesical combination chemotherapy using gemcitabine and MMC appears to be a useful treatment for patients with a history of NMIC which has failed BCG or other intravesical therapy, in addition to patients with intermediate and high-risk disease.

Sign in / Sign up

Export Citation Format

Share Document